The first two authors contributed equally to the article Yes-associated protein 1 (YAPl) is an oncogene that plays multiple roles in the tumorigenesis and progression of many malignances. The present study aimed to investigate the clinical significance of YAPl expression in human osteosarcoma (OS) and explore the molecular mechanisms ofYAPl activity in OS MG-63 cells. The expression of YAPl was assessed by immunohistochemical assay using a tissue microarray procedure. A loss-of-function approach was used to investigate the effects of small hairpin RNA-mediated knockdown of YAPl on the expression of RUNX2, CyclinDl, and matrix metalloproteinase-9 (MMP-9) as well as the proliferative activities and invasive potential in OS MG-63 cells (evaluated by MTT and Transwell assays, respectively). The expression ofYAPl protein in OS
tissues was significantly higher than that in ANCT, and was closely associated with gender (P = 0.013) and Enneking staging (P = 0.035), but it did not correlate with age, tumor location, or distant metastases of OS patients (P > 0.05, each). Knockdown of YAPl resulted in downregulation of the expression of RUNX2, CyclinDl, and MMP-9 and inhibited the proliferation and invasion of MG-63 cells. Our findings suggest that YAPl is highly expressed in OS tissues, and increased expression of this molecule is correlated with the gender and Enneking staging of osteosarcoma patients. Knockdown of YAPl may inhibit the proliferation and invasion of OS cells through downregulation of the RUNX2 pathway, thereby representing a potential therapeutic target for the treatment of cancer.
Osteosarcoma (OS) is the most common type of primary malignant bone tumor and generally follows an aggressive clinical course (1). The high rate of systemic spread that is already observed at the time of diagnosis explains the efficacy ofneoadjuvant and adjuvant chemotherapy and the poor prognosis after radical surgery alone. However, although 5-year survival rates of up to 500/0-70% can be achieved by using current treatment protocols, a substantial group of patients with metastatic, recurrent, and! or refractory disease remains without effective treatment options (2, 3) . Cancer is also a genetic disease, which develops via a multi-step process. Single or multiple mutations in genes related to growth control, invasion, and metastasis form the molecular genetic basis of malignant transformation and tumor progression (4) . Therefore, identification of key genes or targets related to tumorigenesis is crucial for the prevention and treatment of OS.
The Hippo signaling pathway, first identified in Drosophila, is an important regulator of cell proliferation and apoptosis during organ development (5) . Yes-associated protein (YAP), a downstream effector of this pathway, is a transcriptional coactivator that is phosphorylated and inactivated by the Hippo signaling cascade. When Hippo signaling is attenuated, phosphorylation of YAP is reduced, leading to its nuclear localization. Once inside the nucleus, YAP is involved in cell proliferation, survival, and growth. Moreover, YAPplays a key role in the Hippo pathway to control cell proliferation in response to cell contact (6) . YAP may act as an oncogene in mammalian cells. Genome-wide analyses of tumors in a mouse hepatocellular carcinoma (HCC) model and in human HCC have revealed that YAP accelerates tumorigenesis (7) . In a separate study, expression of YAP induced epithelial-mesenchymal transition, suppression of apoptosis, growth factor-independent proliferation, and. anchorageindependent growth, suggesting an oncogenic role for YAP (8) . Furthermore, YAP expression has been reported in several malignant tumors such as human pancreatic ductal adenocarcinoma, colonic adenocarcinoma, lung adenocarcinoma, ovarian serous cystadenocarcinoma, and breast ductal carcinoma (9, 10) . YAP is expressed in the majority of cases of HCC and primarily accumulates in the tumor nucleus. Moreover, the expression of YAP in HCC is significantly associated with poorer tumor differentiation and elevated serum alpha-fetoprotein levels, indicating that YAP is an independent prognostic marker for the overall survival rate of HCC patients and represents a potential therapeutic target for this aggressive malignancy (11).
Importantly, knockdown of YAP in Ewing sarcoma cells resulted in profound inhibition of cell proliferation and anchorage-independent colony formation, suggesting that stabilization and continued expression of YAP is critical for Ewing sarcoma cell growth and tumorigenicity (12) . However, the expression of YAP1 in OS has rarely been reported and, in particular, there is a need to comprehensively explore the role and clinical significance of YAPl in human OS. In the present study, the expression of YAPI in OS tissues was assessed by an immunohistochemical (IHC) assay using a tissue microarray procedure. A loss-of-function approach was employed to observe the effects of small hairpin RNA (shRNA)-mediated knockdown of YAPl on the expression of RUNX2, CyclinD1, and matrix metalloproteinase-9 (MMP-9) in OS MG-63 cells as well as the proliferative activities and invasive potential of MG-63 cells evaluated by MTT and Transwell assays. Our aim was to try to find a novel therapeutic target for the treatment of cancer.
MATERIALSAND METHODS

Materials
The as MG-63 cell line used for experiments was obtained from the Institute of Biochemistry and Cell Biology (Shanghai, China). Lentivirus-mediated YAPI shRNA vector, negative control vector, and virionpackaging elements were purchased from Genechem (Shanghai, China); YAPI and RUNX2 primers were synthesized by ABI (USA). The tissue microarray of human as was purchased from Biomax (USA). All antibodies were obtained from Santa Cruz Biotechnology (USA).
Drugs and reagents
Dulbecco's Modified Eagle medium (DMEM) and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific Inc. (Waltham, MA); TRIzol Reagent and Lipofectamine 2000 were obtained from Invitrogen (Carlsbad, CA); M-MLV Reverse Transcriptase was purchased from Promega (Madison, WI); SYBR Green Master Mix was obtained from Takara (Otsu, Japan); and the ECL Plus Kit was obtained from GE Healthcare (Piscataway, NJ).
Clinical samples and data
A tissue microarray was prepared for the IHC test using a total of 40 consecutive cases of human as tissues and corresponding ANCT, which were collected from the orthopedics department of Shanghai XinHua Hospital from January2007 to December 2011.The baselinecharacteristics of the patients before neo-adjuvant chemotherapy are summarized in Table I . The study was approved by the Medical Ethics Committee ofShanghai Jiaotong University, and written informed consent was obtained from the patients or their parents before sample collection. All of the cases were reviewed by at least two pathologists.
Tissue microarrays
For each case, we selected the tumor foci for construction of the tissue microarrays during routine diagnosis by marking them on the hematoxylin-eosinstained slide using a waterproof pencil. The Advanced Tissue Arrayer (ATA-100; Chemic on International, Tamecula, CA) was used to create holes in a "recipient" paraffin block and to acquire cylindrical core tissue biopsies with a diameter of 1 mm from specific areas ofthe "donor" block. The tissue core biopsies were transferred to the recipient paraffin block at defined array positions. The resulting tissue micro arrays contained tissue samples from 40 formalin-fixed, paraffin-embedded cancer specimens with known diagnosis and correlated benign tumor tissues from patients.
The block was incubated in an oven at 45°C for 20 min to allow complete embedding of the grafted tissue cylinders in the paraffin of the recipient block and then stored at 4°C until microtome sectioning.
Immunohistochemical staining
Anti-YAPI antibody was used for IHC detection of the expression of YAPI protein in tissue microarrays. Tissue microarray sections were processed for IHC analysis of YAP1 protein as follows. Tissue microarrays were incubated with biotinylated antibodies and horseradish peroxidase. Anti-YAP1 antibody was used at a dilution of 1:200. Endogenous peroxidase was inhibited by incubation with freshly prepared 3% hydrogen peroxide with 0.1% sodium azide. Non-specific staining was blocked with 0.5% casein and 5% normal serum. Staining was developed using diaminobenzidine substrate, and sections were counterstained with hematoxylin. Normal serum or PBS was used to replace anti-YAP 1 antibody in negative controls.
Quantification of YAP1 protein expression
YAP1 expression was semiquantitatively estimated as the total YAP1 immunostaining score, which was calculated as the product of a proportion score and an intensity score. The proportion score reflected the fraction of positively stained cells (score 0, <5%; score 1, 5%-10%; score 2, 100/0-50%; score 3, 50%-75%; score 4, >75%). The intensity score represented the staining intensity (score 0, no staining signal; score 1, weak positive signal; score 2, moderate positive signal; score 3, strong positive signal). Finally, a total expression score was given, ranging from 0 to 12. The score 0 was regarded as negative, score 1-3 was regarded as +, score 4-6 was regarded as ++, score 7-9 was regarded as +++, and score 10-12 was regarded as ++++. Two observers estimated the total immunostaining score, independently and blindly. The finally total score reported was the average of two observers.
Cell culture and transfection
MG-63 cells were cultured in DMEM medium supplemented with 10% heat-inactivated FBS, 100UI ml of penicillin, and 100 ug/ml of streptomycin. Cells in this medium were placed in a humidified atmosphere containing 5% CO 2 at 37°C. YAP shRNA and negative controllentivirus were transfected into MG-63 cells. Cells were subcultured at a 1:5 dilution in medium containing 300 ug/ml G418. Positive, stable transfectants were selected and expanded for further study. The YAPI shRNA virus vector-infected clone, the negative control vectorinfected cells, and MG-63 cells were named shYAP1, NC, and CON groups, respectively.
Quantitative real-time peR
ToquantitativelydeterminethemRNAexpressionlevels ofYAP and RUNX2 in the MG-63 cell line, real-time PCR was performed. Total RNA was extracted from each clone using TRIzol according to the manufacturer's protocol. Reverse transcription was carried out using M-MLV and cDNA amplification was performed using the SYBR Green Master Mix kit according to the manufacturer's guidelines. The YAPI gene was amplified using a specific oligonucleotide primer and the human glyceraldehyde-3phosphate dehydrogenase (GAPDH) gene was used as an endogenous control. The PCR primer sequences were as follows: YAP1, 5'-CCTGATGGATGGGAACAAGC-3 , and 5'-GCACTCTGACTGATTCTCTGG-3'; RUNX2, 5'-CUCUGCACCAAGUCCUUUU dTdT-3' and 5'-AAAAGGACUUGGUGCAGAG dTdT-3'; GAPDH, 5'-CAACGAATTTGGCTACAGCA-3' and 5'-AGGGGTCTACATGGCAACTG-3'.
Data were analyzed using the comparative Ct method (2-.6.6C'). Three separate experiments were performed for each clone.
Western blot assay
MG-63 cells were harvested and extracted using lysis buffer (Tris-HCI, SDS, mercaptoethanol, and glycerol). Cell extracts were boiled for 5 min in loading buffer, and then an equal amount of cell extracts was separated on 15% SDS-PAGE gels. Separated protein bands were transferred onto polyvinylidene fluoride (PVDF) membranes, which were subsequently blocked in 5% skim milk powder. Primary antibodies against YAPI , RUNX2, CyclinD1, and MMP-9 were diluted according to the manufacturer's instructions and incubated overnight at 4°C. Subsequently, horseradish peroxidase-linked secondary antibodies were added at a dilution of 1:1000 and incubated at room temperature for 2 h. The membranes were washed 3 times with PBS, and the immunoreactive bands were visualized using the ECL Plus Kit according to the manufacturer's instructions. The relative protein levels in different cell lines were normalized to the concentration ofGAPDH. Three separate experiments were performed for each clone.
Cell proliferation assay
Cell proliferation was analyzed using the MTT assay.
Briefly, cells infected with YAP1 shRNA virus were incubated in 96-well-p1ates at a density of 1 x 10 5 cells per well with DMEM medium supplemented with 10% FBS. Cells were treated with 20 III ofMTT dye at 0, 24, 48, 72, 96, and 120 h, and subsequently incubated with 150 III of DMSO for 5 min. The color reaction was measured at 570 nm using an Enzyme Immunoassay Analyzer (Bio-Rad, Hercules, CA). The proliferation activity was calculated for each clone.
Transwell invasion assay
Transwell filters were coated with Matrigel (3.9 Ilg! Ill; 60-80 Ill) on the upper surface of a polycarbonate membrane (diameter, 6.5 mm; pore size, 811m). After incubating at 37°C for 30 min, the Matrigel solidified and served as the extracellular matrix for analysis oftumor cell invasion. Harvested cells (1 x 10 5 ) in 100 IIIof serumfree DMEM were added into the upper compartment of the chamber. A total of 200 III of conditioned medium derived from NIH3T3 cells was used as a source of chemoattractant, which was placed in the bottom compartment of the chamber. After 24 h of incubation at 37°C with 5% CO 2 , the medium was removed from the upper chamber. The non-invaded cells on the upper side of the chamber were scraped offwith a cotton swab. Cells that had migrated from the Matrigel into the pores of the inserted filter were fixed with 100% methanol, stained with hematoxylin, then mounted and dried at 80°C for 30 min. The number of cells invading through the Matrigel was counted in 3 randomly selected visual fields from the central and peripheral portion of the filter by using an inverted microscope (200 x magnification). Each assay was repeated 3 times.
Statistical analysis SPSS 13.0 was used for statistical analyses. The Kruskal-Wallis H test, chi-square test, and one-way analysis of variance (ANOVA) were employed to analyze the expression rate in all groups. The Wilcoxon rank-sum test was used to analyze the correlation between protein expression and the clinicopathologic features of as patients. The LSD method of multiple comparisons was used when the probability for ANOVA was statistically significant. Significance was defined as P < 0.05.
RESULTS
Expression of YAP1 protein in human as and its association with clinical and pathologic characteristics
The expression of YAPl protein was evaluated using IRe staining. As shown in Fig. l stained negatively for YAP 1 expression (-), 4 stained positively for low YAPI expression (+), 22 stained positively for moderate YAPI expression (++), and 12 stained positively for high YAPI expression (+++). Total score of>2 was used to classify tumor patients with high-YAPI expression group (n = 34), and Total score::;2 was used to classify tumor patients with low-YAP 1 expression group (n = 6). Based on the total scores of the IHC staining, the association between YAPI expression and the various clinical and pathologic features ofas patients was analyzed. As shown in Table II , no significant correlation was found between YAPI expression and age (P = 0.252), tumor location (P = 0.721) or distant metastases of osteosarcoma patients (P = 0.903). However, YAP I expression was significantly correlated with gender and the Enneking staging of osteosarcoma patients (P = 0.013, P = 0.035, respectively). The high expression of YAP 1 protein was more frequently found in osteosarcoma patients at Enneking stages II and III, which suggested that YAP 1 expression might be associated with the progression of osteosarcoma.
Knockdown of YAP] and its effect on RUNX2 expression
To examine whether YAPI could be knocked down by shRNA and the effect ofYAP 1 knockdown on RUNX2 expression in as MG-63 cells, the expression levels of YAPI and RUNX2 were measured. As shown in Fig. 2A-B , clear inhibition of YAPI and RUNX2 mRNA expression was observed in the shYAPI group compared with the NC and CON groups (**P < 0.01, each). The expression levels ofYAP 1 and RUNX2 proteins-as indicated by Western blot assay-were markedly downregulated in the shYAPI group compared with the NC and CON groups (**P < 0.01, each) ( Fig. 2C-F) .
Effect of YAP] knockdown on as cell proliferation
Deregulated cell proliferation is a hallmark of cancer (13) . In order to test the effect of YAP 1 knockdown on as cell growth, we investigated the proliferative activities of MG-63 cells by MTT assay. We found that, YAP 1 knockdown significantly suppressed the proliferative activities ofMG-63 cells in a time-dependent manner compared with the NC Fig. 1 
. The expression of YAP1 protein in human OS examined by IHC (x200). The positive expression of YAP1 protein was mainly detected in the nucleus and cytoplasm ofosteosarcoma cells. A) Negative expression (-); B) Low expression (+); C) Moderate expression (++); D) Strong expression (+++).
and CON groups (Fig. 3A) . CyclinDl is at the heart of many essential cellular processes and plays a role in determining tumor proliferation and the outcome of anticancer treatment. To determine whether YAP1 knockdown suppressed endogenous CyclinD 1 expression through translational repression, the expression of CyclinD1 protein was examined by Western blotting, which revealed decreased expression of Cyc1inD1 protein in the shYAPl group compared with the NC and CON groups (**P< 0.01, each) ( Fig. 3B-C) . This result suggests that YAPI knockdown may inhibit OS cell proliferation via downregulation of CyclinD 1 expression.
Effect ofYAP1 knockdown on OS cell invasion
To determine the effect of YAP1 knockdown on the invasive potential of MG-63 cells, a Transwell assay was carried out. The invasive potential of cells in the Transwell assay was determined by the ability of cells to invade a matrix barrier containing laminin and type IV collagen -the major components of the basement membrane. Representative micrographs of Transwell filters can be seen in Fig. 4A -C. The invasive potential of MG-63 cells was significantly decreased in the shYAPl group compared with the NC and CON groups (**P < 0.01, each) ( Fig.  4D) . Given the important role of MMP-9 in tumor metastasis, Western blotting was performed to investigate the effect of YAP1 knockdown on expression of MMP-9 protein. As shown in Fig. 4£ -F, the expression ofMMP-9 protein was significantly reduced in the shYAPl group compared with the NC and CON groups (**P < 0.01), indicating that YAP1 knockdown may inhibit OS cell invasion through downregulation of MMP-9 expression.
DISCUSSION
OS is the eighth most common form of childhood cancer, comprising 2.4% of all malignancies in pediatric patients and approximately 20% of all primary bone cancers. YAP, the nuclear effector of the Hippo pathway, is a key regulator of organ size and a candidate human oncogene. YAP is widely expressed in human brain tumors (14) and esophageal carcinoma (15) and promotes tumor growth, indicating that YAP is a putative oncogene and represents a potential diagnostic and therapeutic target. In the present study, positive staining for the YAP1 protein was detected in most of as tissues and only in a small section of ANCT. YAP1
expression was significantly higher in as tissues compared with ANCT, which suggested that the carcinogenesis of osteosarcoma might be associated with the accumulation of YAP1. In addition, we analyzed the association between YAP1 expression and various clinical and pathologic features of as, and found high YAP1 expression did not correlate with age, tumor location, or distant metastases of as patients, but was closely associated with gender and Enneking staging, suggesting that upregulation of YAP1 might be correlated with osteosarcoma progression. Therefore, YAPI can be a potential therapeutic target for osteosarcoma.RUNX proteins are DNA-binding transcription factors that regulate the expression of multiple genes involved in cellular differentiation and cell-cycle progression. RUNX2-a master regulator. of osteoblast differentiation that belongs to the runt family oftumor suppressor genesis genetically essential for bone development and osteoblast maturation and is consistently disrupted in as cell lines (17) and pathology specimens (18) . cancer cells (20) . RUNX2 is overexpressed in OS and is a potential biomarker of chemotherapy failure in OS (21) . Importantly, YAP, a mediator of Hippo signaling, interacts with the native RUNX2 protein and suppresses RUNX2 transcriptional activity in a dose-dependent manner. Inhibition of the Yes kinase dissociates endogenous Runx2-YAP complexes (22) (23) (24) . Moreover, the RUNX2 transcription factor cooperates with YAP65 to promote oncogenic transformation (25) . To elucidate the role of YAP1 in OS, a loss-of-function experiment carried out in our study showed that knockdown of YAPI reduced RUNX2 expression and inhibited the growth and invasion of OS MG-63 cells, suggesting that YAP1 may be involved in OS growth and invasion through inactivation of RUNX2 signaling.
CyclinD I is expressed in vanous : tumors and promotes the G liS shift, leading 'to cell proliferation in OS cells (26) . The expression level of CyclinD I clearly correlates with the clinical outcome of disease in OS patients, indicating that CyclinD 1 could be used as a prognostic marker (27) . Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that play a role in tumor metastasis. They are expressed on the tumor cell surface and activate pro-MMPs-thereby exacerbating malignancy-and are considered as powerful indicators of distant metastases of cancer. Specific downregulation of MMP expression causes significant inhibition ofthe migration and invasion of tumor cells, and an anti-MMP monoclonal antibody Fig. 4 . Effect ofYAPl knockdown on OS cell invasion (A-C). The invasive and metastatic potential in Transwell assay was determined on the basis ofthe ability ofcells to invade a matrix barrier containing laminin and type IV collagen, the major components ofthe basement membrane. D) The invasive potential ofMG-63 cells was distinctly decreased in the shYAPl group compared with the NC and CON groups (each **P<O.Ol). E, F) The expression of MMP-9 protein was detected by Western blot assay in OS cells, indicating the decreased expression ofMMP-9 protein in the shYAPl group compared with the NC and CON groups (each **P<O.Ol).
represents a promising probe for future diagnosis of tumors by nuclear medical imaging (28, 29) . Interestingly, RUNX2 protein increases CyclinDI expression (30), promotes MMP-9 expression in bone metastatic cancer cells, and controls cell invasion (31). However, little has been reported about the effect of YAP on RUNX2-mediated MMP-9 and CyclinDl expression in OS. In our study, we showed that knockdown of YAP1 decreased the expression of RUNX2, CyclinD1, and MMP-9 and inhibited the growth and metastasis of OS cells, suggesting that YAPI might be implicated in the development of OS through RUNX2-mediated upregulation of CyclinD1and MMP-9 expression in OS cells.
In summary, our findings suggest that YAPI is highly expressed in the majority of OS tissues compared with ANCT, and is associated with the gender and Enneking staging of OS patients. Knockdown of YAP1 may inhibit the proliferation and invasion of OS cells through inactivation of RUNX2 signaling, representing a potential therapeutic target for the treatment of cancer.
